Herein, we propose a Gal-3-mediated strategy designed to selectively engage pathological cells and disease loci throughout AD progression, offering a paradigm shift in AD-targeted drug delivery by enabling both a spatially and temporally sustained therapeutic intervention. The gene discussed is LGALS3; the disease is Alzheimer disease.